Vasoplegic syndrome is a life-threatening condition characterized by uncontrolled peripheral vasodilation, leading to profound arterial hypotension. Treatments include catecholamines, vasopressin, methylene blue (MB), hydroxocobalamin, angiotensin II, and ascorbic acid. We developed a scoping review protocol according to the Joanna Briggs Institute methodology and searched PubMed, PubMed Central, Scopus, and Cochrane Library electronic databases. A total of 23 records were included in this scoping review, out of which 13 were original research studies, seven were reviews, and three were case studies. In these studies, vasopressin, MB, hydroxocobalamin, angiotensin II, and ascorbic acid were used for vasoplegic syndrome. Vasopressin, MB, hydroxocobalamin, angiotensin II, and ascorbic acid showed rapid restoration of hemodynamics and decreased vasopressor requirement. Non-catecholamine drugs such as vasopressin, angiotensin II, MB, and hydroxocobalamin appear to be promising drugs for the treatment of patients with post-cardiac surgery vasoplegic syndrome. It is demonstrated to be effective in raising blood pressure in such patients, but these agents should be used cautiously due to their associated adverse effects.
Kumar et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: